Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Kratom topic
No spam. Unsubscribe anytime.
Committee weighs kratom options: banning synthetics, testing and cross‑agency work urged
Summary
Lawmakers reviewed HB 407 and heard medical experts, industry groups and regulators recommend distinguishing natural kratom leaf from synthetic derivatives, requiring lab testing and age limits, and coordinating with DPHHS and DOJ for enforcement and data collection before drafting policy.
The committee revisited kratom and the 2025 draft HB 407 during a long public discussion that included regulators, medical professionals, industry representatives and consumer advocates.
Administrators from the Cannabis and Alcohol Regulation Division advised the panel to bring the Department of Public Health and Human Services (DPHHS) and the Department of Justice into the discussion because kratom intersects food‑safety rules, law‑enforcement scheduling questions and FDA authority. CARD officials said the FDA has not approved kratom for food use and that states approach kratom regulation differently.
Medical testimony: Jean Branscum (Montana Medical Association) and other clinicians urged caution and supported limiting access unless the FDA determines safety and efficacy; they flagged cases of addiction and emergency‑room encounters and recommended considering scheduling or strict product controls.
Industry and advocacy testimony: Groups advocating regulated access (Global Kratom Coalition, American Kratom Association affiliates) recommended a Kratom Consumer Protection Act (KCPA) model: preserve access to natural leaf kratom while prohibiting synthetic concentrated derivatives (notably 7‑OH analogs), require independent lab testing, impose age limits, label requirements and prevent marketing to minors. Industry witnesses urged distinguishing leaf products from chemically manipulated concentrates and said many adverse outcomes reported nationally are tied to synthetic or adulterated products sold through unregulated channels.
Law and data: Committee members requested DOJ and DPHHS data about kratom‑related emergency visits, overdoses and toxicology coding. Several members urged improved hospital coding to capture whether kratom/mitragynine was implicated in overdoses so the committee can base policy on clearer evidence patterns.
Next steps: Lawmakers directed staff to compile what other states have done (19 states have passed KCPA‑style laws in varying forms), to coordinate with Law & Justice and DPHHS for data and enforcement perspectives, and to return with an interagency briefing in March that includes DOJ toxicology data, hospital coding guidance and options for statutory language that focuses on synthetic derivatives while considering product testing and retail controls.
